LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

Search

Amicus Therapeutics Inc

Chiusa

SettoreSettore sanitario

7.93 -0.88

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

7.88

Massimo

8.11

Metriche Chiave

By Trading Economics

Entrata

-2.7M

-24M

Vendite

29M

155M

Margine di Profitto

-15.787

Dipendenti

499

EBITDA

-1M

-5.8M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+101.87% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

461M

2.3B

Apertura precedente

8.81

Chiusura precedente

7.93

Notizie sul Sentiment di mercato

By Acuity

19%

81%

33 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Amicus Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 set 2025, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 set 2025, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 set 2025, 21:59 UTC

Utili

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 set 2025, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise as Yen Weakens -- Market Talk

17 set 2025, 23:39 UTC

Discorsi di Mercato

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 set 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 set 2025, 22:18 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 set 2025, 21:00 UTC

Utili

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 set 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

17 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 set 2025, 19:59 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 19:59 UTC

Discorsi di Mercato

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 set 2025, 19:07 UTC

Discorsi di Mercato

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 set 2025, 18:43 UTC

Discorsi di Mercato

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 set 2025, 18:38 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 set 2025, 18:20 UTC

Discorsi di Mercato

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 set 2025, 18:18 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 18:18 UTC

Discorsi di Mercato

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 set 2025, 18:14 UTC

Discorsi di Mercato

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 set 2025, 17:59 UTC

Discorsi di Mercato

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 set 2025, 17:15 UTC

Acquisizioni, Fusioni, Takeovers

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 set 2025, 17:06 UTC

Acquisizioni, Fusioni, Takeovers

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 set 2025, 16:51 UTC

Utili

Correct: Exor 1H Net Loss -EUR624M

17 set 2025, 16:34 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 16:34 UTC

Discorsi di Mercato

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 set 2025, 16:25 UTC

Utili

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 set 2025, 16:23 UTC

Utili

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Confronto tra pari

Modifica del prezzo

Amicus Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

101.87% in crescita

Previsioni per 12 mesi

Media 16.17 USD  101.87%

Alto 20 USD

Basso 12 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Amicus Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

6

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

5.925 / 7.38Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

33 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
help-icon Live chat